Isofol Medical AB (publ)
ISOFOL.ST · Health Technology · Biotechnology · SE
11 employees · isofolmedical.com
About
Isofol Medical AB (publ) is a Swedish company that was founded in 2006 and is listed on the Nasdaq Stockholm exchange. The company focuses on the development of medical solutions for a wide range of diseases, with a particular emphasis on cancer treatment. Isofol's main product is Modufolin, a proprietary technology that is an advancement of the well-known drug Folic Acid, commonly used in cancer therapy. Modufolin has a longer duration in the body, making it more effective in inhibiting tumor cell growth. Isofol also has a diagnostic division that specializes in developing tests for detecting Vitamin B12 levels in the body, which are crucial for identifying diseases such as dementia and anemia.
Annual results
Reported figures, SEK
| Year | Revenue | Net income | Net margin | Free cash flow |
|---|---|---|---|---|
| 2025 | — | -54.0M | — | — |
| 2024 | — | -43.0M | — | — |
| 2023 | — | -37.0M | — | — |
| 2022 | 12.0M | -159M | -1325.0% | — |
| 2021 | 22.0M | -200M | -909.1% | — |
Dividends per share
ISOFOL.ST in MarketPulse
The live chart with RSI and moving averages, the price, news, signals and price alerts for Isofol Medical AB (publ) are inside MarketPulse — currently in private beta.
Company data by Eulerpool. Logos provided by Elbstream. Reported figures, not investment advice.